Trends in the use of immunotherapy to treat soft tissue sarcoma

被引：1

作者：

Iwai, Yoshiko ^{[1
]}

Baldwin, Xavier L. ^{[1
]}

Feeney, Timothy ^{[2
]}

Agala, Chris B. ^{[1
]}

Yanagihara, Ted K. ^{[3
]}

Stein, Jacob N. ^{[4
]}

Kim, Hong Jin ^{[5
]}

Spanheimer, Philip M. ^{[5
]}

机构：

[1] Univ North Carolina Chapel Hill, Dept Surg, Chapel Hill, NC USA

[2] Univ North Carolina Chapel Hill, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA

[3] Univ North Carolina Chapel Hill, Dept Radiat Oncol, Chapel Hill, NC USA

[4] Univ North Carolina Chapel Hill, Dept Med Oncol, Chapel Hill, NC USA

[5] Univ North Carolina Chapel Hill, Dept Surg, Div Surg Oncol, Chapel Hill, NC USA

来源：

AMERICAN JOURNAL OF SURGERY | 2024年 / 236卷

关键词：

Sarcoma; Soft tissue sarcoma; Soft tissue mass; Immunotherapy; Immune checkpoint inhibitor; SURVIVAL; INSIGHTS; CANCER; TUMORS;

D O I：

10.1016/j.amjsurg.2024.115794

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background: The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS. Methods: This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011-2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt. Results: Of the 103,092 patients with STS, 1935 (1.9 %) received or were recommended IO therapy. IO use increased 10-fold (0.24 %-2.5 % from 2011 to 2021; p < 0.0001). Patients had higher odds of receiving IO when having higher grade tumors and metastatic disease, and when treated at an academic research center (all p < 0.001). Conclusions: IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.

引用

页数：8